| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,250,000 |
| Market
Cap: |
65.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.6 - $9.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sesen Bio is a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. Co.'s main product candidate Vicinium (VB4-845), is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive carcinoma in situ of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Guerin. Co.'s lead systemically-administered product candidate, VB6-845d, is being developed as a treatment for multiple types of EpCAM-positive solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
1,428,721 |
| Total Sell Value |
$0 |
$0 |
$0 |
$838,716 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
10 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Modernatx, Inc. |
10% Owner |
– – • |
2023-03-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,059,338 |
|
-22% |
|
| Torok Michael |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
I/I |
369,991 |
50,000 |
|
- |
|
| Torok Michael |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
51,250 |
51,250 |
|
- |
|
| Ugwumba Chidozie |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
I/I |
2,215,877 |
2,215,877 |
|
- |
|
| Klichinsky Michael |
Chief Scientific Officer |
• – – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
484,347 |
484,347 |
|
- |
|
| Zweifach Sanford S |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
413 |
413 |
|
- |
|
| Hodits Regina |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
I/I |
2,297,546 |
2,297,546 |
|
- |
|
| Morrison Briggs |
Director |
– • – |
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,175 |
12,175 |
|
- |
|
| Forbes Monica |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
S |
$0.59 |
$203,013 |
D/D |
(345,849) |
505,664 |
|
23% |
|
| Forbes Monica |
Chief Financial Officer |
• – – |
2023-03-02 |
4 |
OE |
$0.59 |
$217,850 |
D/D |
371,125 |
603,968 |
|
- |
|
| Macdonald Glen C |
Chief Technology Officer |
• – – |
2023-03-02 |
4 |
S |
$0.59 |
$100,008 |
D/D |
(170,372) |
398,918 |
|
23% |
|
| Macdonald Glen C |
Chief Technology Officer |
• – – |
2023-03-02 |
4 |
OE |
$0.59 |
$168,053 |
D/D |
286,292 |
432,806 |
|
- |
|
| Sullivan Mark |
General Counsel & Secretary |
• – – |
2023-03-02 |
4 |
S |
$0.59 |
$128,681 |
D/D |
(219,218) |
378,651 |
|
23% |
|
| Sullivan Mark |
General Counsel & Secretary |
• – – |
2023-03-02 |
4 |
OE |
$0.59 |
$175,029 |
D/D |
298,175 |
423,530 |
|
- |
|
| Ryu Elly |
Principal Accounting Officer |
• – – |
2023-03-02 |
4 |
S |
$0.59 |
$10,149 |
D/D |
(17,289) |
148,624 |
|
23% |
|
| Cannell Thomas R |
President and CEO |
• • – |
2023-03-02 |
4 |
S |
$0.59 |
$286,155 |
D/D |
(487,487) |
672,386 |
|
23% |
|
| Cannell Thomas R |
President and CEO |
• • – |
2023-03-02 |
4 |
OE |
$0.59 |
$356,192 |
D/D |
606,800 |
950,950 |
|
- |
|
| Macdonald Glen C |
Chief Technology Officer |
• – – |
2023-02-21 |
4 |
S |
$0.59 |
$15,227 |
D/D |
(25,927) |
282,998 |
|
24% |
|
| Ryu Elly |
Principal Accounting Officer |
• – – |
2023-02-21 |
4 |
S |
$0.59 |
$4,204 |
D/D |
(7,159) |
165,913 |
|
24% |
|
| Cannell Thomas R |
President and CEO |
• • – |
2023-02-21 |
4 |
S |
$0.59 |
$31,554 |
D/D |
(53,727) |
553,073 |
|
24% |
|
| Forbes Monica |
Chief Financial Officer |
• – – |
2023-02-21 |
4 |
S |
$0.59 |
$36,332 |
D/D |
(61,862) |
480,388 |
|
24% |
|
| Sullivan Mark |
General Counsel & Secretary |
• – – |
2023-02-21 |
4 |
S |
$0.59 |
$23,393 |
D/D |
(39,831) |
299,694 |
|
24% |
|
| Duker Jay S. |
Director |
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
| Jewett Michael A. S. |
Director |
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
| Keyes Jason A |
Director |
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
95 Records found
|
|
Page 1 of 4 |
|
|
0.02 (1.25%) 
